Listed

XBiotech Inc.: Form 10-Q for the period ended Mar 31, 2018

Filed with the SEC on May 8, 2018 and accepted by EDGAR at May 8, 2018, 15:23 ET.

Share

Management's discussion and analysis

As filed, 15,270 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

XBiotech Inc. (“XBiotech” or the “Company) is a pre-market biopharmaceutical company engaged in discovering and developing True Human™ monoclonal antibodies for treating a variety of diseases. True Human™ monoclonal antibodies are those which occur naturally in human beings—as opposed to being derived from animal immunization or otherwise engineered. We believe that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts. XBiotech is focused on developing its True Human™ pipeline and manufacturing system.

We have never been profitable and, as of March 31, 2018, we had an accumulated deficit of $220.6 million. We had net losses of $4.1 million and $10.6 million for the three months ended March 31, 2018 and 2017, respectively. We expect to incur significant and increasing operating losses for the foreseeable future as we advance our drug candidates from discovery through preclinical testing and clinical trials and seek regulatory approval and eventual commercialization. In addition to these increasing research and development expenses, we expect general and administrative costs to increase as we add personnel and continue to operate as a public company. We will need to generate significant revenues to achieve profitability, and we may never do so. As of March 31, 2018, we had 40 employees.

Recent Events:

The Company recently announced the launch of two separate Phase 2, open label, dose escalation studies evaluating a new subcutaneous formulation of the Company’s True Human™ monoclonal antibody, MABp1, in patients with moderate to severe Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Dose ranging of this subcutaneous formulation for MABp1 is planned to be studied in 4 week and 12 week open label treatment regimens for AD and HS, respectively. These findings will establish the basis for potential further randomized studies with the subcutaneous formulation.

The Company continues to be subject to a number of risks common to companies in similar stages of development. Principal among these risks are the uncertainties of technological innovations, dependence on key individuals, development of the same or similar technological innovations by the Company’s competitors and protection of proprietary technology. The Company’s ability to fund its planned clinical operations, including completion of its planned clinical trials, is expected to depend on the amount and timing of cash receipts from future collaboration or product sales and/or financing transactions. The Company believes that its cash and cash equivalents of $28.0 million at March 31, 2018 will enable the Company to achieve some key inflection points, including advanced clinical studies in certain indication(s), as well as on-going R&D efforts for the Company’s pre-clinical pipeline. Based on our research and development plans and our timing expectations related to the progress of our programs, we expect that our cash and cash equivalents as of March 31, 2018 will enable us to fund our operating expenses and capital expenditure requirements through 2019. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.

Revenues

To date, we have not generated any revenue. Our ability to generate revenue and become profitable depends on our ability to successfully commercialize our lead product candidate, Xilonix™, or any other product candidate we may advance in the future.

Research and Development Expenses

Research and development expense consists of expenses incurred in connection with identifying and developing our drug candidates. These expenses consist primarily of salaries and related expenses, stock-based compensation, the purchase of equipment, laboratory and manufacturing supplies, facility costs, costs for preclinical and clinical research, development of quality control systems, quality assurance programs and manufacturing processes. We charge all research and development expenses to operations as incurred.

Clinical development timelines, likelihood of success and total costs vary widely. We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates. From inception through March 31, 2018, we have recorded total research and development expenses, including share-based compensation, of $173.0 million. Our total research and development expenses for the three months ended March 31, 2018 and 2017 were $3.0 million and $8.2 million, respectively. Share-based compensation accounted for $0.1 million and $0.3 million for the three months ended March 31, 2018 and 2017, respectively.

Research and development expenses, as a percentage of total operating expenses for the three months ended March 31, 2018 and 2017 were 72% and 80%, respectively. The percentages, excluding stock-based compensation, for the three months ended March 31, 2018 and 2017, were 72% and 83%, respectively.

Our clinical development costs decreased with the completion and discontinuation of our phase III colorectal cancer clinical trials under EMA and FDA jurisdictions, respectively.

The clinical development costs may increase going forward with the recent launch of the two phase 2 dermatology studies which may potentially be followed by more advanced studies and as we evaluate our pipeline and plan potential new studies.

Based on the results of our preclinical studies, we anticipate that we will select drug candidates and research projects for further development on an ongoing basis in response to their preclinical and clinical success and commercial potential. For research and development candidates in early stages of development, it is premature to estimate when material net cash inflows from these projects might occur.

General and Administrative Expenses

General and administrative expense consists primarily of salaries and related expenses for personnel in administrative, finance, business development and human resource functions, as well as the legal costs of pursuing patent protection of our intellectual property and patent filing and maintenance expenses, stock–based compensation, and professional fees for legal services. Our total general and administration expenses for the three months ended March 31, 2018 and 2017 were $1.2 million and $2.1 million, respectively. Share-based compensation accounted for $22 thousand and $430 thousand for the three months ended March 31, 2018 and 2017, respectively.

General and administrative expense, as a percentage of total operating expenses for the three months ended March 31, 2018 and 2017 were 28% and 20%, respectively. The percentages, excluding stock-based compensation, for the three months ended March 31, 2018 and 2017, were 28% and 17%, respectively.

Critical Accounting Policies

The preparation of financial statements in conformity with generally accepted accounting principles requires us to make judgments, estimates and assumptions in the preparation of our consolidated financial statements and accompanying notes. Actual results could differ from those estimates. We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form 10-K for the year ended December 31, 2017.

Results of Operations

Revenue

We did not record any revenue during the three months ended March 31, 2018 and 2017.

Expenses

Research and Development

Research and Development costs are summarized as follows (in thousands):

Three Months Ended March 31, 2018 2017 Increase (Decrease) % Increase (Decrease)
Salaries and related expenses $1,051 $2,213 $(1,162) -53%
Laboratory and manufacturing supplies 213 1,232 (1,019) -83%
Clinical trials and sponsored research 8 3,155 (3,147) -100%
Stock-based compensation 88 294 (206) -70%
Other 1,633 1,294 339 26%
Total $2,993 $8,188 $(5,195) -63%

We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates.

Research and development expenses decreased by $5.2 million to $3.0 million for the three months ended March 31, 2018, compared to $8.2 million for the three months ended March 31, 2017. The decrease was due to a $3.1 million decrease of clinical trial activities and sponsored research expense, related to the completion of all active trials. Labor costs also decreased due to the reduced size of the research and development workforce from 93 to 35. In addition, the decrease in laboratory and manufacturing supplies expense occurred due to a reduction in clinical trial drug manufacturing.

General and Administrative

General and administrative costs are summarized as follows (in thousands):

Three Months Ended March 31, 2018 2017 Increase (Decrease) % Increase (Decrease)
Salaries and related expenses $324 $469 $(145) -31%
Patent filing expense 181 186 (5) -3%
Stock-based compensation 22 430 (408) -95%
Professional fees 207 415 (208) -50%
Other 423 583 (160) -27%
Total $1,157 $2,083 $(926) -44%

General and administrative expense decreased $0.9 million to $1.2 million for the three months ended March 31, 2018, compared to $2.1 million for the three months ended March 31, 2017. The decrease was primarily related to stock–based compensation expenses of $0.4 million, due to the forfeiture of terminated employees’ stock options. Professional fees also decreased $0.2 million due to the reduction of public relations activities. The decrease in labor costs was mainly due to the reduction of our general and administrative workforce from 10 to 5.

Other income (loss)

The following table summarizes other income (loss) (in thousands):

Three Months Ended March 31, 2018 2017
Interest income $64 $49
Foreign exchange gain (loss) 17 (341)
Total $81 $(292)

19

The $64 thousand of interest income for the three months ended March 31, 2018 is mainly from the interest generated from the Company’s Canadian bank account. Foreign exchange gain was mainly due to the fluctuation between US dollar and Euro in the three months ended March 31, 2018 compared to the three months ended March 31, 2017.

Liquidity and Capital Resources

Our cash requirements could change materially as a result of the progress of our research and development and clinical programs, licensing activities, acquisitions, divestitures or other corporate developments.

Since our inception on March 22, 2005 through March 31, 2018, we have funded our operations principally through public offerings and the private placement of equity securities, which have provided aggregate cash proceeds of approximately $257.4 million. The following table summarizes our sources and uses of cash (in thousands):

Net cash (used in) provided by: Three Months Ended March 31, 2018 2017
Operating activities $(3,526) $(11,908)
Investing activities (34) (607)
Financing activities 201 32,713
Effect of foreign exchange rate on cash and cash equivalents 7 110
Net change in cash and cash equivalents $(3,352) $20,308

During the three months ended March 31, 2018 and 2017, our operating activities used net cash of $3.5 million and $11.9 million, respectively. The use of net cash in each of these periods primarily resulted from our net losses. The decrease in net loss from operations for the three months ended March 31, 2018 as compared to the three months ended March 31, 2017 was mainly due to the decrease in clinical trials and sponsored research expense and salaries and related expenses.

During the three months ended March 31, 2018 and 2017, our investing activities used net cash of $34 thousand and $607 thousand, respectively. The use of cash was for the purchase of new research and development equipment.

During the three months ended March 31, 2018 and 2017, our financing activities provided net cash proceeds of $0.2 million and $32.7 million, respectively. During the three months ended March 31, 2018, employees exercised stock options to purchase a total of 80,500 shares of our common stock for approximately $0.2 million in net proceeds. During the three months ended March 31, 2017, we entered into subscription agreements with accredited investors, and sold 2.4 million common shares at $13 per share for approximately $31.6 million in net proceeds. Also, we sold 87 thousand shares under a Common Stock Sales Agreement with H.C. Wainwright & Co. LLC for net proceeds of approximately $1.0 million. Employees exercised stock options to purchase a total of 66 thousand shares of common stock for a total of approximately $0.3 million in net proceeds.

We expect to continue to incur substantial operating losses in the future. We will not receive any product revenue until a drug candidate has been approved by the EMA or similar regulatory agencies in other countries and successfully commercialized. As of March 31, 2018, our principal sources of liquidity were our cash and cash equivalents, which totaled approximately $28.4 million.

Contractual Obligations and Commitments

On January 12, 2008, we entered a lease agreement to lease our office space in Austin, Texas. On September 15, 2010, we entered into a second lease agreement to lease additional space in Austin, Texas. On March 20, 2013, we extended the lease for an additional 21 months on the same terms and rental rates as the current lease. On February 28, 2015, we extended the lease for another 4 years. The future minimum lease payments are as follows as of March 31, 2018 (in thousands):

Contractual Obligations Total Less than 1 Year 1 - 3 Years More than 3 years
Operating facility leases $433 $433 $— $—
Total contractual obligations $433 $433 $— $—

Rent expense was $200 thousand and $186 thousand for the three months ended March 31, 2018 and 2017, respectively.

Off-Balance Sheet Arrangements

Since inception, we have not engaged in any off-balance sheet activities, including the use of structured finance, special purpose entities or variable interest entities.

Market risk

As filed, 308 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company is not currently exposed to material market risk arising from financial instruments, changes in interest rates or commodity prices, or fluctuations in foreign currencies. The Company has no need to hedge against any of the foregoing risks and therefore currently engages in no hedging activities.

Controls and procedures

As filed, 1,804 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Management's Evaluation of our Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out by the Company’s management, with the participation of the Chief Executive Officer and Principal Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on such evaluation, the Chief Executive Officer and Principal Financial Officer concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports the Company files or furnishes under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and are operating in an effective manner.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the first quarter of the year ended December 31, 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Risk factors

As filed, 837 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2017. Please carefully consider the information set forth in this Quarterly Report on Form 10-Q and the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K, as well as other risks and uncertainties, could materially and adversely affect our business, results of operations and financial condition, which in turn could materially and adversely affect the trading price of shares of our Common Stock. Additional risks not currently known or currently material to us may also harm our business.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2018-01-01 to 2018-03-31$3.0mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2018-01-01 to 2018-03-31−$4.2mus-gaap:OperatingIncomeLoss
Net income3 months2018-01-01 to 2018-03-31−$4.1mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-01-01 to 2018-03-31−$0.11us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2018-01-01 to 2018-03-31−$3.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2018-01-01 to 2018-03-31$34.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2018-03-31$28.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-03-31$29.7mus-gaap:AssetsCurrent
Total assetsAt period end2018-03-31$58.9mus-gaap:Assets
Current liabilitiesAt period end2018-03-31$2.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-03-31$2.5mus-gaap:Liabilities
Shareholders' equityAt period end2018-03-31$56.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001171843-18-003654. Last ingested by Listed: Nov 14, 2026, 18:14 ET. Listed shows no prices and gives no investment advice.